CV Risk Beyond LDL!


Cardiovascular (CV) disease is the leading cause of mortality in the US and globally contributing to more than 17 million deaths worldwide. For years, lowering LDL-cholesterol has been one of the primary targets for reducing CV risk, with statins as the established treatment. Recently, new science has emerged and is changing the landscape of how cardiologists and the broader CV team reduce CV risk in their patients. The goal of this page is to provide a resource to highlight the most relevant content on the emerging science in CV risk beyond LDL. Curated content will include new cutting-edge science along with foundational policy, education, and tools.


   Guidelines and Policy
    Patient Cases

   Journal Scans
    Expert Analysis
 
 
 
 
 
 
 
 
 

   Clinical Tools & Patient Resources    Other Articles 

   Images & Slides
 
 
 



We are grateful to these distinguished Members of the American College of Cardiology who contributed to this collection.

This collection is supported by Amarin

 

Android App Download IOS App Download Powered By